Baxter International BAX Indemnifications related to kidney care separation

Other financials

Revenue$2.7B+2.9%

Gross profit$891.0M+3.5%

Operating income$66.0M+13.8%

Net income-$15.0M-112%

EPS (diluted)-$0.03-112%

Cash & equivalents$2.0B-12.1%

Total debt$224.0M-8.9%

Total equity$6.0B-14.7%

Total assets$19.8B-6.8%

Operating cash flow$213.0M+210%

CapEx$128.3M+15.0%

Free cash flow$83.0M-42.1%

Market cap$10.27B-50.6%

Enterprise value$8.48B-55.6%

P/S0.9×-1.0×

Gross margin30.1%-5.9pp

Operating margin-2.7%—

Net margin-9.7%+62.5pp

FCF margin3%-2.4pp

Return on equity-16.7%-76.7pp

Debt / equity0×0.0×

Current ratio1.9×-0.2×

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept bax:BusinessSeparationIndemnificationLiability.

The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Baxter International's indemnifications related to kidney care separation?: Baxter International (BAX) reported indemnifications related to kidney care separation of $53M in Q1 2026.